Skip to main content
Galvanta Pharma
  • Company
  • Services
  • Manufacturing
  • Quality
  • Portfolio
  • Business
  • Regulatory
  • Safety
  • Contact
Khmer
MenuClose menu
  • Company
  • Services
  • Manufacturing
  • Quality
  • Portfolio
  • Business
  • Regulatory
  • Safety
  • Contact

Medicine information and clinical decisions

GALVANTA COMPANY LIMITED provides corporate information through galvanta.com. The website and its enquiry routes do not provide a clinical service.

Effective: 23 September 2026. Last reviewed: 23 September 2026.
On this pageProduct identitiesIndividual careUrgent situationsReporting a suspected problemEnquiries and personal informationChanges and corrections

Product identities

A record may identify a substance, strength, form or presentation and pack. It is not an approved label, summary of product characteristics, patient leaflet, prescription or treatment protocol.

The company holds no product registration or marketing authorisation for the presentations described on this website.

Authorisation of another company’s medicine containing the same substance does not establish authorisation, equivalence or suitability of a listed presentation.

Individual care

The website does not provide diagnosis, dose selection, titration, interaction checking, contraindication screening or advice to start, change or stop treatment.

Do not interpret total pen contents, injection concentration or tablet strength as a treatment instruction. A qualified healthcare professional should address individual care using the information applicable to the patient, medicine and jurisdiction.

Urgent situations

For urgent medical help, seek emergency medical care or consult a qualified healthcare professional. Do not wait for an email reply or attempt to resolve an emergency through the enquiry form.

Reporting a suspected problem

A suspected adverse event is an unwanted medical occurrence after use of a medicine, whether or not the medicine caused it.

Reports concerning an item bearing, or represented as connected with, the company’s name can be sent using the Adverse-event reporting guidance. Product defects and recall correspondence are addressed in the Product-quality notice.

Reporting to the company does not replace direct reporting to a competent authority or a professional’s statutory responsibilities.

Enquiries and personal information

Send general medicine-record questions to [email protected]. Identify the record and country concerned without sending unnecessary patient information.

The mailbox is shared with other company enquiries. Read the Privacy notice before sending health-related details.

Changes and corrections

This notice may change with the website’s scope. Report errors to the public email address. The stated date identifies the current version; it does not indicate approval of a medicine.

Galvanta Pharma

GALVANTA COMPANY LIMITED

A Cambodian company in the pharmaceutical sector, established in Cambodia.

Company registration number 1000634930.

The company holds no pharmaceutical manufacturing licence, GMP certificate, product registration or marketing authorisation.

Official Facebook page

Company information

  • Company
  • Manufacturing
  • Quality
  • Regulatory information
  • Services
  • Product records
  • Business enquiries
  • Contact

Reporting

  • Adverse events
  • Product-quality concerns and recalls
  • Suspected falsification
  • Business conduct
  • Website security

Contact

[email protected]

Registered office

Shop No. 2F-60, Sihanoukville Special Economic Zone
Preah Sihanouk Province, Cambodia

Website policies

  • Legal notice and policies

© 2026 GALVANTA COMPANY LIMITED. Rights reserved to the extent provided by law.

LegalTermsPrivacyCookiesSitemap
English|Khmer